Eribulin Monomethanesulfonate
Triple-Negative Breast Carcinoma
Explore 428 assets in Triple-Negative Breast Carcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06590558CT.gov Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT06355037CT.gov Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06355024CT.gov Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT05760378CT.gov Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | — | Recruiting | — | — | — |
NCT04502680CT.gov Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT04345913CT.gov Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05546255CT.gov Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT03579472CT.gov M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT02120469CT.gov Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02225470CT.gov Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT01372579CT.gov Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eribulin Monomethanesulfonate (this asset) | National Cancer Institute (NCI) | P3 | B · 63 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Eribulin Monomethanesulfonate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 69 |
| Breast Neoplasm | — | P4 | BB · 69 |
| Toxic Encephalopathy | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eribulin Monomethanesulfonate in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eribulin-monomethanesulfonate-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →